These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 19009183)

  • 1. [Effect of a hydrophilic formulation of topical paromomycin on cutaneous leishmaniasis among patients with contraindications for treatment with pentavalent antimonials].
    Santos AM; Noronha EF; Ferreira LA; Carranza-Tamayo CO; Cupolillo E; Romero GA
    Rev Soc Bras Med Trop; 2008; 41(5):444-8. PubMed ID: 19009183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate.
    Faghihi G; Tavakoli-kia R
    Clin Exp Dermatol; 2003 Jan; 28(1):13-6. PubMed ID: 12558620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment of New World cutaneous leishmaniasis with a combination of topical paromomycin/methylbenzethonium chloride and injectable meglumine antimonate.
    Soto J; Hernandez N; Mejia H; Grogl M; Berman J
    Clin Infect Dis; 1995 Jan; 20(1):47-51. PubMed ID: 7727669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study.
    Soto J; Fuya P; Herrera R; Berman J
    Clin Infect Dis; 1998 Jan; 26(1):56-8. PubMed ID: 9455509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis.
    Armijos RX; Weigel MM; Calvopiña M; Mancheno M; Rodriguez R
    Acta Trop; 2004 Jul; 91(2):153-60. PubMed ID: 15234664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major.
    Shazad B; Abbaszadeh B; Khamesipour A
    Eur J Dermatol; 2005; 15(2):85-7. PubMed ID: 15757817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Viannia) braziliensis.
    de Morais-Teixeira E; Aguiar MG; Soares de Souza Lima B; Ferreira LA; Rabello A
    J Antimicrob Chemother; 2015 Dec; 70(12):3283-90. PubMed ID: 26346991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis.
    Moosavi Z; Nakhli A; Rassaii S
    Int J Dermatol; 2005 Dec; 44(12):1064-5. PubMed ID: 16409282
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy of paromomycin ointment in the treatment of cutaneous leishmaniasis: results of a double-blind, randomized trial in Isfahan, Iran.
    Iraji F; Sadeghinia A
    Ann Trop Med Parasitol; 2005 Jan; 99(1):3-9. PubMed ID: 15701249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tamoxifen and meglumine antimoniate combined therapy in cutaneous leishmaniasis patients: a randomised trial.
    Machado PRL; Ribeiro CS; França-Costa J; Dourado MEF; Trinconi CT; Yokoyama-Yasunaka JKU; Malta-Santos H; Borges VM; Carvalho EM; Uliana SRB
    Trop Med Int Health; 2018 Sep; 23(9):936-942. PubMed ID: 29924907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical paromomycin for New World cutaneous leishmaniasis.
    Sosa N; Pascale JM; Jiménez AI; Norwood JA; Kreishman-Detrick M; Weina PJ; Lawrence K; McCarthy WF; Adams RC; Scott C; Ransom J; Tang D; Grogl M
    PLoS Negl Trop Dis; 2019 May; 13(5):e0007253. PubMed ID: 31048871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should we continue to indicate meglumine antimoniate as first-line treatment for cutaneous leishmaniasis in Tunisia.
    Mlika RB; Hamida MB; Hammami H; Jannet SB; Badri T; Fenniche S; Mokhtar I
    Dermatol Ther; 2012; 25(6):615-8. PubMed ID: 23210761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Successful topical treatment of chronic cutaneous leishmaniasis with paromomycin sulfate (15%) and methylbenzethonium chloride (12%)].
    Schallreuter KU; Lemke KR
    Hautarzt; 1994 Nov; 45(11):783-6. PubMed ID: 7822205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment of American cutaneous leishmaniasis: controlled study.
    Krause G; Kroeger A
    Clin Infect Dis; 1999 Aug; 29(2):466-7. PubMed ID: 10476776
    [No Abstract]   [Full Text] [Related]  

  • 15. Successful treatment of cutaneous leishmaniasis with intralesional meglumine antimoniate: A case series.
    Arboleda M; Barrantes S; Úsuga LY; Robledo SM
    Rev Soc Bras Med Trop; 2019 May; 52():e20180211. PubMed ID: 31141044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intralesional treatment with meglumine antimoniate in three patients with New World cutaneous leishmaniasis and large periarticular lesions with comorbidities.
    Pimentel MIF; Vasconcellos ÉCFE; Ribeiro CO; Lyra MR; Saheki MN; Salgueiro MM; Antonio LF; Schubach AO
    Rev Soc Bras Med Trop; 2017; 50(2):269-272. PubMed ID: 28562769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis.
    Arevalo I; Tulliano G; Quispe A; Spaeth G; Matlashewski G; Llanos-Cuentas A; Pollack H
    Clin Infect Dis; 2007 Jun; 44(12):1549-54. PubMed ID: 17516397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review.
    Brito NC; Rabello A; Cota GF
    PLoS One; 2017; 12(9):e0184777. PubMed ID: 28926630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Meglumine Antimoniate and Miltefosine in Cutaneous Leishmaniasis.
    Rahman A; Tahir M; Naveed T; Abdullah M; Qayyum N; Malik DH; Amin B
    J Coll Physicians Surg Pak; 2023 Dec; 33(12):1367-1371. PubMed ID: 38062590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru.
    Miranda-Verástegui C; Llanos-Cuentas A; Arévalo I; Ward BJ; Matlashewski G
    Clin Infect Dis; 2005 May; 40(10):1395-403. PubMed ID: 15844060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.